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CD8+ T cells are critical players of the immune 
response to viruses, intracellular bacteria, proto-
zoan parasites, and tumor cells. Upon recogni-
tion of antigenic peptide–MHC-I complexes, 
CD8+ T cells are activated, undergo a profound 
clonal expansion and differentiate into effector 
CTLs with the ability to lyse a broad range of 
infected  cells,  and  produce  specific  cytokines 
(van Stipdonk et al., 2001; Kaech et al., 2002). 
CTLs kill through granule exocytosis mediated 
by the membrane drilling protein perforin and 
the release of granzymes (Voskoboinik et al., 
2006). After the expansion phase, the majority 
of effector cells die, leaving behind a small pop-
ulation of memory cells able to respond very   
efficiently  by  undergoing  rapid  proliferation   
and acquisition of effector function. The differ-
entiation of naive CD8+ T cells into CTLs, 
the execution of the effector program, and the   
generation of the memory CD8+ T cells rely on 
several transcription factors. Elevated levels   
of the transcription factor T-bet are essential   
for  the  generation  of  the  short-lived  Klrg1hi 
IL-7Rlo effector CD8+ T cells (Joshi et al., 2007).   
The related transcription factor Eomes plays a 
critical role in the expression of the effector 
molecules perforin, granzyme B and IFN-, 
whereas T-bet seems to have a more redundant 
function in this regard (Szabo et al., 2002; Pearce 
et al., 2003; Intlekofer et al., 2005). Eomes plays 
a complex role in the generation of memory 
CD8+ T cells, including the control of IL-15R 
expression (Intlekofer et al., 2005; Takemoto   
et al., 2006). Runx3 is another transcription fac-
tor that regulates the expression of perforin, 
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CD8+ T lymphocytes mediate the immune response to viruses, intracellular bacteria, proto-
zoan parasites, and tumors. We provide evidence that the transcription factor Bcl11b/Ctip2 
controls hallmark features of CD8+ T cell immunity, specifically antigen (Ag)-dependent 
clonal expansion and cytolytic activity. The reduced clonal expansion in the absence of 
Bcl11b was caused by altered proliferation during the expansion phase, with survival  
remaining unaffected. Two genes with critical roles in TCR signaling were deregulated in 
Bcl11b-deficient CD8+ T cells, CD8 coreceptor and Plc1, both of which may contribute to 
the impaired responsiveness. Bcl11b was found to bind the E8I, E8IV, and E8V, but not E8II 
or E8III, enhancers. Thus, Bcl11b is one of the transcription factors implicated in the  
maintenance of optimal CD8 coreceptor expression in peripheral CD8+ T cells through 
association with specific enhancers. Short-lived Klrg1hiCD127lo effector CD8+ T cells  
were formed during the course of infection in the absence of Bcl11b, albeit in smaller 
numbers, and their Ag-specific cytolytic activity on a per-cell basis was altered, which  
was associated with reduced granzyme B and perforin.
© 2010 Zhang et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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2007). Additionally, germ line removal of 
Bcl11b blocks  selection of thymocytes in 
relation with altered rearrangements at the 
TCR- locus (Wakabayashi et al., 2003) 
and  affects  the  nervous  system  develop-
ment, namely, specification of the cortico-
spinal motor neurons (Arlotta et al., 2005) 
and subcortically projecting axons (Chen   
et al., 2008).
Bcl11b  is  also  expressed  in  mature   
T lymphocytes; however, its role in these 
cells has not been addressed because of the 
block at the DP stage of thymocyte devel-
opment upon its removal with the CD4-
Cre deleter (Albu et al., 2007). In this study, we conditionally 
removed Bcl11b in mature T cells, and its absence resulted   
in reduced antigen (Ag)-specific clonal expansion of CD8+  
T cells during infection and in vitro. Furthermore, although the 
short-lived Klrg1hiIL7Rlo effector CD8+ T cells were formed 
in the absence of Bcl11b, the execution of the effector pro-
gram by CTLs, determined by their ability to kill Ag-specific 
targets and produce perforin and granzyme B, was altered.   
In addition, we found that Bcl11b controls Ag-specific clonal 
expansion of CD8+ T cells during infection by regulating 
maintenance of CD8 coreceptor expression in the periphery, 
through association with E8I, E8IV, and E8V enhancers and 
by controlling expression of Plc1. These results demonstrate, 
for the first time, that Bcl11b is a critical transcription factor 
for CD8+ T cell immunity by regulating genes of major im-
portance for CD8+ T cells.
RESULTS
Removal of BCL11B in peripheral CD8+ T lymphocytes with 
the use of the dLck-iCre deleter
Bcl11b is expressed in mature CD4+ and CD8+ T cells (Fig. 1) 
in addition to thymocytes (Albu et al., 2007). Its removal 
granzyme B, and IFN- (Chen et al., 2008; Cruz-Guilloty   
et al., 2009). Finally, Bcl6 and the related Bcl6b control the 
generation and maintenance of memory cells (Ichii et al.,   
2002; Manders et al., 2005), whereas Id2 is required for mem-
ory CD8+ T cells survival (Cannarile et al., 2006).
Bcl11b is a C2H2 zinc finger transcription factor that we 
initially identified as a mediator of the transcriptional repres-
sion function of the orphan nuclear receptors of the COUP-TF 
family (Avram et al., 2000). Bcl11b directly binds GC-rich 
response elements to mediate transcriptional repression of re-
porters driven by such elements (Avram et al., 2002; Cismasiu 
et al., 2005) and is a general transcriptional repressor of the 
HIV-I LTR in CD4+ T cells (Cismasiu et al., 2008). Bcl11b 
also participates in the transcriptional activation of specific tar-
get genes in the immune system, such as IL-2 and Cot kinase 
(Cismasiu et al., 2006; Cismasiu et al., 2009), findings which 
demonstrate its complex role in the regulation of gene expres-
sion in immune system. Conditional removal of Bcl11b at the 
double-positive (DP) stage of T cell development shows that 
this transcription factor is critical for positive selection of both 
CD4 and CD8 SP thymocytes and for survival of DP thymo-
cytes, which is, in part, independent of Bcl2/Bcl-xl (Albu et al., 
Figure 1.  Removal of Bcl11b in mature T cells 
with the dLck-iCre deleter. (A) Flow cytometry 
analysis of Bcl11b in gated CD4+ and CD8+ T lym-
phocytes from spleen, and in CD4 and CD8 SP and 
DP thymocytes of Bcl11bF/F/dLck-iCre (KO) and  
control mice (WT). Single cell suspensions of spleens 
and thymi were stained for CD4, CD8, and Bcl11b. 
This is a representative experiment out of three,  
with three pairs of mice. (B) FACS analysis of  
thymocytes of Bcl11bF/F/dLck-iCre (KO) and control 
mice (WT). (C) FACS analysis of T cells from spleens 
and lymph nodes of Bcl11bF/F/dLck-iCre (KO) and 
control mice (WT) and spleens from Bcl11bF/F/dLck-
iCre/OT-1 and OT-1 control mice. (D) Total cellular-
ity of CD8+ T cells. Absolute numbers were derived 
based on the percentage of CD8+ T cells in total live 
cells. A two-tailed Student’s t test was applied to 
determine statistical significance. P = 0.0133.  
In B–D, data are derived from 4–10 pairs of mice. 
Error bars indicate SD.JEM VOL. 207, August 2, 2010 
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Bcl11b-deficient CD8+ T cells have poor Ag-specific clonal 
expansion in vivo
The efficient removal of BCL11B in the CD8+ T lympho-
cytes of Bcl11bF/F/dLck-iCre mice, and the fact that these 
mice still have substantial numbers of CD8+ T cells in the 
periphery which are not affected by developmental defects, 
makes Bcl11bF/F/dLck-iCre mice an appropriate model to 
study the CD8+ T cell immune response in the absence of 
Bcl11b. For this purpose, we crossed the Bcl11bF/F/dLck-
iCre mice onto an OT-1 background (Fig. 1 C), in which 
the  majority  of  CD8+  T  cells  express  a  TCR  (V2V5) 
which recognizes the OVA peptide residues 257–264 pre-
sented in the context of H-2K(b) (Hogquist et al., 1994). We 
further used an adoptive transfer system and infection with 
Listeria monocytogenes expressing Ova (Lm-Ova; Shen et al., 
1995) to evaluate the immune response. Specifically, we co-
transferred equal numbers of naive CD62LhiCD44lo CD45.2/
OT-1  Bcl11b-deficient  and  CD62LhiCD44lo  CD45.1/2/
OT-1 WT CD8+ T cells in CD45.1 recipient mice. After the 
transfer, we infected the recipient mice with Lm-Ova and 
evaluated the expansion of Bcl11b-deficient and WT CD8+ 
T cells, based on the CD45.1 and CD45.2 allelic differences. 
We found that CD45.1/2 WT CD8+ T cells expanded sig-
nificantly, reaching a peak at day 7 of infection, and then de-
clined in number during the contraction phase (Fig. 2, A and B). 
The peak of expansion for Bcl11b-deficient CD8+ T cells 
was also at day 7; however, the magnitude of the expansion 
with the CD4-Cre deleter caused a block in positive selection 
with marked reduction of T cells in the periphery, which   
presented  developmental  abnormalities  (Albu  et  al.,  2007), 
therefore impeding the study of Bcl11b role in mature T cells. 
To circumvent this problem, we crossed Bcl11bF/F mice with 
the dLck (Lck distal) promoter–iCre mice, taking into account 
that the dLck promoter is active in mature T cells (Wildin et al., 
1995; Zhang et al., 2005). We observed efficient removal of the 
floxed Bcl11b allele in CD8+ T cells, whereas the removal in 
CD4+ T lymphocytes was less efficient (Fig. S1), which is con-
sistent with previous observations showing higher activity of 
the dLck-iCre in CD8+ T cells (Zhang et al., 2005; D’Souza 
et al., 2008). Quantitative evaluation by flow cytometry indi-
cated that the floxed allele was removed in 90% of the CD8+  
T cells (Fig. 1 A), which is similar to previous results for other 
genes (Zhang et al., 2005; D’Souza et al., 2008). Bcl11b was still 
present in DP thymocytes, as well as in CD4 and CD8 SP thy-
mocytes of Bcl11bF/F/dLck-iCre mice (Fig. 1 A and Fig. S1).
CD8 and CD4 SP thymocytes were present in Bcl11bF/F/
dLck-iCre mice in similar percentages to those of WT (Fig. 1 B), 
and the TCR- levels were similar to those of the WT cells, 
indicating that these cells reached maturity (Fig. S2). There 
was a modest but significant reduction in the percentage and 
absolute numbers of CD8+ T cells in the lymph nodes and 
spleens of Bcl11bF/F/dLck-iCre mice, whereas the reduction 
in the CD4+ T cell numbers was less remarkable (Fig. 1,   
C and D; and not depicted).
Figure 2.  Bcl11b-deficient CD8+ T cells have a 
defect in expansion during the immune response 
to Lm-Ova and influenza infection. (A) Expansion 
of Bcl11b-deficient and WT OT-1 CD8+ T cells in 
spleen during the course of infection with LM-Ova. 
Naive CD62LhiCD44lo CD8+ T lymphocytes from 
CD45.2 Bcl11bF/F/dLck-iCre/OT-1 and CD45.1/2/OT-1 
mice (1:1; total 104) were cotransferred in CD45.1 
recipient mice. The next day after transfer, mice were 
infected with 1.5 × 104 CFU Lm-Ova, and the im-
mune response was monitored by evaluating the 
frequency of CD45.2 (Bcl11b deficient) and CD45.1/2 
(WT) CD8+ T cells on days 6, 7, 9, and 12 after infec-
tion. This is representative data from four indepen-
dent experiments in which cells were transferred 
from three mice from each group into three to four 
recipients. (B) Graph depicting the expansion of 
Bcl11b-deficient and WT OT-1 CD8+ T cells in spleen 
at the indicated time points after Lm-Ova infection, 
as described in A. Data are expressed as mean ± SD 
of the percentage of donor CD8+ T lymphocytes and 
a mean of four independent experiments. (C) Influenza-
specific Bcl11b-deficient and WT CD8+ T cells in the 
mediastinal lymph nodes on day 10 after influenza 
infection. Mixed bone marrow chimeras were gener-
ated by reconstitution of lethally irradiated CD45.1 with either a 1:1 mix of CD45.1 and CD45.2 bone marrows (WT/WT chimeras) or a 1:1 mix of CD45.1 
and Bcl11bF/F/dLck-iCre bone marrows (WT/KO chimeras). After reconstitution, mice were infected with 1,000 EIU PR8. The frequencies of NP-specific and 
PA-specific CD8+ T cells derived from each donor type were determined by flow cytometry. The numbers in each plot refer to the mean percentage ± SD 
of CD8+ T cells that are either NP- or PA-specific. Data are representative for six pairs of donor mice, in which there were five mice reconstituted from 
each pair.1690 CD8+ T cell responsiveness requires Bcl11b | Zhang et al.
incorporation of BrdU in transferred OT-1 cells on day 6   
after the Lm-Ova infection to determine whether their Ag-
specific proliferation was altered. We found that the per-
centage of CD8+ T cells that had incorporated BrdU was 
reduced in Bcl11b-deficient OT-1 CD8+ T cells compared 
with the WT OT-1 cells (Fig. 3 A). In addition, we evalu-
ated the forward scatter of the CD8+ T cells as a measure-
ment of T cell size, which increases after activation and before 
division (Grumont et al., 2004). Our results clearly indicate 
that the population with high forward scatter was reduced   
in the Bcl11b-deficient CD8+ T cells compared with WT 
CD8+ T cells (Fig. 3 B), which is consistent with fewer pro-
liferating cells in this population.
To determine whether the reduction in the CD8+ T cell 
numbers during the course of infection was caused by en-
hanced cell death, we evaluated the apoptosis of Bcl11b- 
deficient and WT CD8+ T cells by measuring the levels of 
cleaved  caspase-3.  We  found  that  a  similar  percentage  of 
Bcl11b-deficient CD8+ T cells stained positively for cleaved 
caspase-3 compared with WT on days 6, 7, 9, or 12 after   
infection (Fig. 3 C and Fig. S3), demonstrating that the reduc-
tion in the number of Bcl11b-deficient CD8+ T cells during 
the course of infection is not a result of increased cell death.
Reduced proliferation of Bcl11b-deficient CD8+ T cells  
is caused by multiple alterations in TCR signaling
To directly measure the proliferative response of the OT-1 
CD8+ T cells to antigenic stimulation, we labeled Bcl11b-
deficient and WT naive OT-1 CD8+ T cells with CFSE, in-
cubated them with APCs loaded with OVA257-264 peptide, 
and  monitored  their  proliferation  by  dilution  of  CFSE. 
Bcl11b-deficient CD8+ T cells showed decreased proliferation 
was dramatically reduced (Fig. 2, A and B). In addition, the 
numbers of CD45.2 Bcl11b-deficient CD8+ T cells remained 
lower compared with the numbers of WT cells during the 
contraction phase of the immune response (Fig. 2, A and B). 
Similar results were observed when knockout and WT OT-1 
CD8+ T cells were transferred separately in recipient mice 
(unpublished data), suggesting that the defect in expansion 
was not a result of the competition by WT cells.
To determine whether similar defects in expansion were 
also observed in a polyclonal CD8+ T cell response, we next 
investigated the ability of Bcl11b-deficient CD8+ T cells   
to expand in response to infection with influenza virus.   
In these experiments, irradiated CD45.1 recipient mice were 
reconstituted  with  Bcl11bF/F/dLck-iCre  (CD45.2)  and  WT 
(CD45.1/2) bone marrow cells, and the mixed chimeras were 
infected  with  a  sublethal  dose  (1,000  egg  infectious  units 
[EIU])  of  A/PR8/34  influenza  8  wk  after  reconstitution. 
The  frequency  of  influenza  nucleoprotein  NP-specific,  as 
well  as  influenza  acidic  polymerase  (PA)–specific,  CD8+  
T cells was evaluated in mediastinal lymph nodes. The results 
show  that  the  frequency  of  NP-specific  or  PA-specific 
Bcl11b-deficient CD8+ T cells was >10-fold decreased com-
pared with WT (Fig. 2 C). These results show that even on a 
polyclonal background, Bcl11b-deficient CD8+ T cells have 
a poor expansion in response to infection, which is similar to 
the results obtained with the OT-1/Lm-Ova model.
Bcl11b-deficient CD8+ T cells have reduced Ag-specific 
proliferation, but they do not die more during the 
expansion or contraction phases of the immune response
To further investigate the cause of the reduced expansion   
of the Bcl11b-deficient CD8+ T cell, we first evaluated the 
Figure 3.  Proliferation and survival of Bcl11b-
deficient OT-1 CD8+ T cells in vivo after Ag-
specific activation. (A) Proliferation at day 6 after 
infection was evaluated by BrdU incorporation 16 h 
after the i.p. injection of BrdU in mice cotransferred 
with KO and WT cells and then infected with Lm-Ova, 
as described in Fig. 2. BrdU incorporation was evalu-
ated within the donor Bcl11b-deficient CD45.2 and WT 
CD45.1/2 CD8+ T cell populations. (B) Forward scatter 
of the CD8+ T cells was evaluated in the same conditions 
as in A. (C) Survival of Bcl11b-deficient and WT CD8+ T 
cells during the course of infection with Lm-Ova. Cleaved   
caspase-3 was evaluated within the donor Bcl11b-
deficient CD45.2 and WT CD45.1/2 CD8+ T cell popula-
tions at the indicated time points. Bcl11b-deficient  
CD45.2 and WT CD45.1/2 CD8+ T cells were transferred 
in CD45.1 recipient mice further infected with Lm-Ova, 
as described in Fig. 2. Histograms show levels of 
cleaved caspase-3 on gated CD45.2 (Bcl11b-deficient) or 
CD45.1/2 (WT) CD8+ T cell populations versus isotype 
control (filled histogram). Numbers indicate the  
percentage of cells within the gated populations. Levels 
of cleaved caspase-3 in recipient CD8+ T cells are indi-
cated in Fig. S3 as an internal control. Data in A–C  
are representative of three independent experiments.JEM VOL. 207, August 2, 2010 
Article
1691
by amplifying the Ag-specific TCR response and Ag-specific 
proliferation (Veillette et al., 1989; Arcaro et al., 2001; Holler 
and Kranz, 2003). To further demonstrate that that the al-
tered expression of CD8 coreceptor causes diminished TCR 
signaling, we activated the CD8+ T cells by treatment with 
-TCR/CD8/CD28 and evaluated the phosphorylation of 
Zap70. Our results demonstrate that Zap70 phosphorylation 
was diminished after TCR/CD8 corecptor/CD28 engage-
ment in Bcl11b-deficient CD8+ T cells (Fig. 5 C), suggesting 
that one of the causes of the reduced proliferation of Bcl11b-
deficient CD8+ T cells is decreased CD8 coreceptor levels.
The reduced levels of CD8 coreceptor could not be the 
sole cause of the reduced proliferation of Bcl11b-deficient 
CD8+ T cells because stimulation with -CD3/CD28 anti-
bodies also resulted in reduced proliferation but substan-
tially improved. Considering that PMA/ionomycin treatment 
brought the expansion of Bcl11b-deficient CD8+ T cells to 
WT levels (Fig. 4 D), we hypothesized that there might be a 
second defect in Bcl11b-deficient CD8+ T cells, upstream of 
PKC-. We found that an additional gene with central role 
in TCR signaling presented altered mRNA levels in Bcl11b-
deficient CD8+ T cells, specifically Plc1 (phospholipase C 
gamma 1; Wilde and Watson, 2001; Bonvini et al., 2003; 
microarray analysis, unpublished data), and demonstrated by 
qRT-PCR that the Plc1 mRNA levels were reduced in 
Bcl11b-deficient CD8+ T cells (Fig. 5 D). Calcium flux was 
attenuated in Bcl11b-deficient CD8+ T cells after activation 
of CD8+ T cells with -CD3/CD28 antibodies, supporting 
the observation with regard to Plc1 expression (Fig. 5 E). 
All these data collectively demonstrate that deregulated ex-
pression of Plc1, together with the reduced CD8 coreceptor 
in response to Ag-specific stimulation compared with WT 
(Fig. 4 A). In addition, the up-regulation of the early activa-
tion marker CD69, a measurement of TCR activation, was 
reduced in response to stimulation with OVA257-264 peptide-
loaded APCs (Fig. 4 B). We further investigated the ability of 
Bcl11b-deficient CD8+ T cells to proliferate in response to 
stimulation with -CD3/CD28 antibodies and found that 
though the proliferation was substantially improved, it did 
not reach the same levels as in WT (Fig. 4 C). However, 
when the cells were stimulated with PMA/ionomycin, pro-
liferation of Bcl11b-deficient CD8+ T cells reached the WT 
levels (Fig. 4 D). These results suggest that the reduced pro-
liferation of Bcl11b-deficient CD8+ T cells is likely to be 
caused by altered TCR signaling, with a potential defect up-
stream of CD3 engagement, and a second defect upstream of 
PKC-. The levels of both TCR and CD28 were equivalent 
in Bcl11b-deficient OT1 CD8+ T cells (unpublished data), 
although on a polyclonal background we observed a slight 
reduction in TCR and CD3 levels (unpublished data). Inter-
estingly, the CD8 coreceptor levels were reduced in Bcl11b-
deficient CD8+ T cells (Fig. 5 A and Table S1). The reduction in 
the CD8 coreceptor levels was not only observed in Bcl11bF/F/ 
dLck-iCre mice but also when Bcl11b was removed from 
CD8+ T cells with the use of the ER-Cre deleter in vivo 
(Fig. S4). We conducted quantitative (q) RT-PCR and dem-
onstrated that CD8 and  coreceptor mRNAs were lower 
in the absence of Bcl11b (Fig. 5 B), suggesting that the reduc-
tion in the coreceptor levels is caused by a decrease in the co-
receptor gene expression.
It has been demonstrated that the CD8 coreceptor plays a 
critical role in CD8+ T cell activation and immune response 
Figure 4.  In vitro proliferation of 
Bcl11b-deficient and WT CD8+ T cells in 
response to TCR stimulation. (A) Bcl11b-
deficient and WT naive OT-1 CD8+ T cells were 
labeled with CFSE and incubated for 3 d with 
0.1 µM OVA257-264 peptide-loaded APCs. Num-
bers of cell divisions of WT or knockout cells 
were measured by CFSE dilution. The frequency 
of cells in each CFSE dilution peak is given. 
Data are representative of three independent 
experiments. (B) Response of Bcl11b-deficient 
and WT naive OT-1 CD8+ T lymphocytes to TCR 
stimulation. Bcl11b-deficient and WT naive 
OT-1 CD8+ T cells were cultured with OVA257-264 
peptide-pulsed APCs for 5 h. Cells were  
then stained for CD8 and CD69 and analyzed 
by flow cytometry. Histograms represent  
surface levels of CD69 within the gated CD8+ 
T cells. Data are representative of three inde-
pendent experiments, in which two to three 
pairs of mice were used. (C and D) In vitro  
proliferation in response to stimulation  
with -CD3/CD28 antibodies (C) and PMA/
ionomycin (D), evaluated as in A. Data are 
representative of two independent experiments 
with two pairs of mice.1692 CD8+ T cell responsiveness requires Bcl11b | Zhang et al.
E8I, EIV, and E8V enhancers but not with E8II and E8III 
enhancers (Fig. 6). E8I and E8II control the CD8 corecep-
tor levels in mature CD8+ T cells. In addition, E8II and 
E8III together control the CD8 coreceptor levels in DP 
thymocytes  (Ellmeier  et  al.,  1997,  1998;  Hostert  et  al., 
1997; Kioussis and Ellmeier, 2002; Feik et al., 2005). How-
ever, maintenance of the CD8 coreceptor genes expression 
in the periphery seems to be complex, as even in the ab-
sence of E8I and E8II, CD8+ T cells still maintain much of 
their coreceptor expression (Ellmeier et al., 2002). It has 
been suggested that other enhancers, such as EIV and EV, 
and/or other mechanisms, might be involved in the main-
tenance of CD8 expression in the periphery (Kioussis and 
expression  in  Bcl11b-deficient  CD8+  T  lymphocytes,  are 
likely to contribute to the reduced Ag-specific proliferation 
and expansion in vivo and in vitro.
Bcl11b controls expression of the CD8 coreceptor  
by association with specific enhancers
Regulation of CD8 expression by Bcl11b raised the ques-
tion of whether Bcl11b directly controls the expression of 
CD8 coreceptor genes by binding to the CD8 enhancers. 
We conducted chromatin immunoprecipitations (ChIPs) 
to determine whether Bcl11b associates with any of the 
CD8 enhancers, including E8I, E8II, E8III, EIV, and E8V. 
Our ChIP assays demonstrated that Bcl11b associated with 
Figure 5.  Bcl11b regulates expression of CD8 
coreceptor and Plc1 genes. (A) Surface and intra-
cellular levels of CD8 and CD8 coreceptors. Single 
cell suspensions from lymph nodes of Bcl11bF/F/dLck-
iCre and control mice were stained for surface or in-
tracellular CD8 and CD8. Overlayed histograms 
indicate surface or intracellular CD8 and CD8. CD8 
and CD8 MFIs are also indicated. Representative data 
for five pairs of mice are shown. (B) Relative mRNA 
levels of the CD8 coreceptor in sorted naive CD44lo 
Bcl11b-deficient and WT CD8+ T lymphocytes from 
four (CD8a) and three (CD8b) pairs of mice, normalized 
to actin. A two-tailed Student’s t test was applied to 
determine statistical significance. P = 3.66 × E4, and 
0.006. (C) Immunoblot analysis of Zap70 phosphoryla-
tion after TCR, CD8, and CD28 cross-linking of purified 
CD8+ T cells from OT1 mice. CD8+ T cells were purified 
by depletion, and CD8+ T cells were preincubated with 
the indicated biotinylated antibodies, followed by addi-
tion of streptavidin. 106 cells were used in each treat-
ment. P-Zap70 was quantified by densitometric 
analysis versus total Zap70. Data are representative for 
two pairs of mice. (D) Relative Plcg1 mRNA levels in 
Bcl11b-deficient (KO) and WT (WT) CD8+ T cells from 
four pairs of mice, normalized to actin. * indicates 
significant difference. Error bars indicate SD. P = 0.05. 
(E) Calcium flux analysis in Bcl11b-deficient (KO) and 
WT (WT) CD8+ T cells. Lymphocytes were loaded with 
Fluo4 and surface stained for CD4 and CD8. Cells were 
preincubated with biotinylated -CD3/CD28, after which streptavidin was added (arrow), and the fluorescence was measured for the indicated period of time. 
The histogram on the right indicates the fluorescence after addition of ionomycin to record the maximal calcium response. Calcium flux was analyzed using 
the kinetics platform of FlowJo and represented as Fluo4 fluorescence over time. This is a representative experiment out of three.
Figure 6.  BCL11B associates with the E8I, E8IV, and E8V enhancers. ChIPs with anti-Bcl11b or IgG antibodies on purified CD8+ T cells. The associa-
tion of Bcl11b with the CD8 enhancers was evaluated by qPCR using previously described primers (Sato et al., 2005), which cover the indicated regions of 
the enhancers. Binding is expressed relative to the input and calculated as indicated in Materials and methods. Data are representative of four indepen-
dent experiments with four independent pairs of mice.JEM VOL. 207, August 2, 2010 
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basis (Fig. 7 B), suggesting that Bcl11b-deficient CD8+ T cells 
might have defects in CTL activity.
The effector population is formed in the absence of Bcl11b 
during the Lm-Ova infection, albeit in smaller number, and 
the effector cells produce less perforin and granzyme
One  cause  for  the  poor  Ag-specific  cytolytic  activity  of 
Bcl11b-deficient  CTLs  might  be  defective  differentiation 
into short-lived effector cells, which up-regulate Klrg1 and 
down-regulate CD127, during the immune response (Kaech 
et al., 2003). Our results show that Bcl11b-deficient OT-1 
CD8+ T cells differentiated normally into Klrg1hiCD127lo ef-
fector population (Fig. 8 A); however, the absolute numbers 
of effector cells was reduced overall (not depicted). Indeed, 
the reduced numbers of effector cells may account for the in-
creased bacterial burden. However, in the ex vivo killing as-
says, equal numbers of CD8+ T cells from LM-Ova–infected 
Bcl11bF/F/dLck-iCre/OT-1 and WT OT-1 mice were used. 
Even in these conditions, Bcl11b-deficient CTLs presented 
reduced Ag-specific killing activity, demonstrating that the 
reduced killing activity is not only a result of reduced num-
bers of CTLs. Thus, the reason for poor cytolytic activity 
could be caused by a reduction in the cytolytic effector mol-
ecules, perforin, and granzyme B. We found that the levels of 
granzyme B were reduced in Bcl11b-deficient CTLs at the 
peak of infection with LM-Ova (Fig. 8 B). In addition, the 
CD8+ T cells purified from LM-Ova–infected Bcl11bF/F/
dLck-iCre/OT1 mice presented a major reduction in the 
perforin levels, compared with equal numbers of OT1 WT 
cells (Fig. 8 C). We also investigated the perforin and gran-
zyme B mRNA levels in equal numbers of CD8+ T cells pu-
rified  from  LM-Ova–infected  Bcl11bF/F/dLck-iCre/OT1 
and OT1 mice and found lower levels of both mRNAs in the 
absence of Bcl11b (Fig. 8 D).
We further determined, by ChIP assays, whether Bcl11b 
associates with the genomic regions upstream of the tran-
scription start sites (TSSs) of perforin and granzyme B genes 
in CD8+ T cells purified from LM-Ova–infected mice. Our 
data demonstrated that Bcl11b associated with the genomic 
Ellmeier, 2002). Our results show that Bcl11b is present on 
several enhancers of the CD8 coreceptor genes, including 
E8I, E8IV, and E8V and through these multiple associa-
tions perhaps contributes to the maintenance of optimal 
expression levels of the CD8 coreceptor genes in the pe-
riphery. The remaining expression of CD8 coreceptor in 
the absence of Bcl11b may be attributed to the E8II en-
hancer, to which Bcl11b did not bind (Fig. 6), as well as to 
other transcription factors that control the E8I, E8IV, and 
E8V enhancers. Overall, our data demonstrate that Bcl11b 
is one of the transcription factors implicated in the mainte-
nance of CD8 coreceptor expression in peripheral CD8+  
T cells, potentially through direct association with some of 
the CD8 gene enhancers.
Bcl11b-deficient CTLs fail to clear LM-Ova and have poor 
Ag-specific killing activity
Because  effective  CTLs  are  required  for  the  control  of   
L. monocytogenes, we next evaluated the bacterial clearance medi-
ated by Bcl11b-deficient CD8+ T cells. In these experiments 
Bcl11b-deficient and WT OT-1 CD8+ T cells were trans-
ferred to separate recipient mice, which were then infected 
with Lm-Ova. We found that bacterial titers were much 
higher in recipients of Bcl11b-deficient OT-1 CD8+ T cells 
than in recipients of normal OT-1 CD8+ T cells (Fig. 7 A). 
Bacterial clearance was also impaired when Bcl11bF/F/dLck-
iCre/OT-1 and WT OT-1 mice were directly infected with 
Lm-Ova (unpublished data).
Because reduced bacterial clearance may be caused by the 
reduced  Ag-specific  expansion  of  Bcl11b-deficient  CD8+  
T cells, we further evaluated ex vivo, on a per cell basis,   
the Ag-specific killing activity of CTLs purified from LM-
Ova–infected mice. Specifically, we compared equal numbers 
of Bcl11b-deficient and WT OT-1 CTLs purified from Lm-
Ova–infected OT-1 mice for Ag-specific cytotoxic activity 
against MEC.B7.SigOva target cells, expressing OVA257-264 
peptide via MHC class I (van Stipdonk et al., 2001). Our re-
sults clearly show that in the absence of Bcl11b, CTLs killed 
OVA257-264-expressing target cells less efficiently on a per cell 
Figure 7.  Evaluation of bacterial burden and Ag-specific cytolytic activity in the absence of Bcl11b from CD8+ T cells. (A) Bacterial burden was 
assessed in the livers of Lm-Ova–infected mice, separately transferred with Bcl11b-deficient and WT OT-1 CD8+ T cells, on days 3, 4, and 5 after infection. 
CFUs were normalized to milligrams of tissue. Three independent experiments were conducted, each with three pairs of mice. (B) Ex vivo killing of Ag-specific 
targets by Bcl11b-deficient and WT OT-1 CD8+ T cells was evaluated by measuring lactate dehydrogenase activity released into the media after killing of  
target cells, as described in the Materials and methods. Bcl11b-deficient and WT OT-1 CD8+ T cells were purified from spleens of Lm-Ova–infected mice on  
day 5 after infection and incubated with MEC.B7.SigOva cells expressing OVA257-264 peptide via MHC class I (van Stipdonk et al., 2001). Data are presented  
as means ± SD of cytotoxicity (lactate dehydrogenase activity) of triplicate samples and are representative of three independent experiments.1694 CD8+ T cell responsiveness requires Bcl11b | Zhang et al.
Figure 8.  Evaluation of effector population and effector molecules in the absence of Bcl11b from CD8+ T cells. (A) The formation of effector 
population during the immune response to Lm-OVA infection was evaluated in Bcl11b-deficient and WT donor OT-1 CD8+ T cells on days 6, 7, 9, and 12 
after infection by staining for Klrg1 and CD127. The boxes indicate the Klrg1hiCD127lo and Klrg1loCD127hi populations gated on the donor CD45.2 Bcl11b-
deficient and CD45.1/2/ WT CD8+ T cells. Data are representative of three independent experiments. (B) Granzyme B was evaluated on day 7 after the  
Lm-Ova infection within the donor Bcl11b-deficient CD45.2 and WT CD45.1/2 CD8+ T cell populations. Experiments were conducted as described in Fig. 2. 
Numbers indicate the percentage of cells in the gated populations. The histograms on the right show granzyme B in CD8+ T cells from uninfected mice. Data 
are representative of three independent experiments in which cells were transferred from two to three mice from each group in three to four recipients.  JEM VOL. 207, August 2, 2010 
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with L. monocytogenes or influenza and produced less perforin 
and granzyme B. Bcl11b-deficient CD8+ T cells presented 
reduced Ag-specific proliferation, but not increased apop-
tosis, during the course of the immune response. TCR signaling 
after  Ag-specific  activation  is  required  for  naive  CD8+  
T lymphocytes to enter cell cycle and expand. After infection, 
the majority of Bcl11b-deficient CD8+ T lymphocytes were 
found blocked in G0/G1 (unpublished data). Furthermore, 
Bcl11b-deficient  CD8+  T  lymphocytes  presented  reduced 
up-regulation of the early activation marker CD69 after 
TCR activation, which is suggestive of altered TCR signal-
ing. In terms of the mechanism of the reduced expansion 
during the immune response, we found that the CD8 core-
ceptor levels were reduced in the absence of Bcl11b. CD8 
coreceptor genes not only play a critical role in the CD8 line-
age development (Fung-Leung et al., 1991; Crooks and   
Littman, 1994) but also in proliferative response of CD8+ T cells   
(Cai and Sprent, 1994). CD8 coreceptor contributes to TCR 
binding to peptide–MHC class I complexes on APCs (Garcia 
et al., 1996), and it induces a conformational change in the 
CD3, which is important for TCR signaling (Gil et al., 2008). 
In addition, the coreceptor amplifies TCR signaling, through 
partitioning, together with the TCR complex, to the lipid 
rafts and association with p56lck (Arcaro et al., 2001). Bcl11b 
regulated CD8 coreceptor gene expression through associa-
tion with the E8I enhancer, which is known to play a role   
in the CD8 coreceptor expression in mature CD8+ T cells 
(Ellmeier et al., 1997, 1998; Hostert et al., 1997; Kioussis and 
Ellmeier, 2002; Feik et al., 2005). In addition, Bcl11b was 
found to be present on E8IV and E8V enhancers, whose role 
in the control of CD8 expression is less characterized. Al-
though the regulation of CD8 coreceptor expression during 
development  has  been  well  characterized  (Ellmeier  et  al., 
1997, 1998; Hostert et al., 1997; Kioussis and Ellmeier, 2002; 
Feik et al., 2005), not much is known about the regulation 
and maintenance of its expression in the peripheral CD8+  
T cells. In the absence of Bcl11b, the levels of the CD8 core-
ceptor were reduced but not abrogated, which is consistent 
with the idea that other transcription factors play roles in 
controlling the activity of the E8I, E8IV, and E8V enhancers. 
In addition to this, Bcl11b might also regulate expression of CD8 
coreceptors indirectly by regulating other transcription factors 
implicated in this process, such as MAZR (Bilic et al., 2006). 
region between 452 and 1000 upstream of the perforin   
gene TSS (Fig. 8 E) but not to the distal CTL-specific DNase I   
hypersensitive site (Pipkin et al., 2007; Cruz-Guilloty et al., 
2009; Fig. S5). Bcl11b also associated with the granzyme B 
genomic region from 13 to 1309 upstream of TSS (Fig. 8 F) 
but not with a genomic region localized 1 kb downstream of 
the granzyme B gene stop codon (Fig. S5). The ratios of the 
CD8 mean fluorescence intensity (MFI) between Bcl11b- 
deficient and WT CD8+ T cells during T cell activation, as well 
as in CD8+ T cells isolated from LM-Ova–infected mice, re-
mained similar to the ratio of CD8+ T cells from naive mice 
(Table S2), suggesting that it is unlikely that further reduction 
in CD8 levels during the activation might contribute to the 
reduction in effector molecules.
All  these  results  collectively  demonstrate  that  Bcl11b- 
deficient CD8+ T cells have reduced cytolytic activity in vivo 
in response to infection and, ex vivo, against Ag-specific tar-
gets. The reduced cytolytic activity in vivo correlates with 
decreased ability of Bcl11b-deficient CTLs to produce perfo-
rin and granzyme B during LM-Ova infection.
We further used the ER-Cre system for inducible re-
moval of Bcl11b in an in vitro culture system for CTL differ-
entiation (Cruz-Guilloty et al., 2009). Specifically, we first 
activated CD8+ T cells from Bcl11bF/F/ER-Cre and ER- 
Cre mice, after which the cells were grown in media con-
taining OH-tamoxifen. Under these in vitro conditions, and 
with removal of the gene after the activation of the CD8+  
T cells, the perforin and granzyme B mRNA levels were similar 
in Bcl11bF/F/ER-Cre and ER-Cre CD8+ T cells (Fig. 8,   
G and H). Thus, removal of Bcl11b after in vitro activation of 
CD8+ T cells does not result in down-regulation of perforin 
and granzyme B mRNA levels, suggesting that the in vivo 
reduction of perforin and granzyme B and the reduced cyto-
lytic activity might be secondary to suboptimal TCR acti-
vation, at least in part.
DISCUSSION
In this paper, we provide evidence that Bcl11b is a critical 
transcription factor for CD8+ T cell immune response by 
controlling two critical aspects of the CD8 immunity: Ag-
specific  expansion  in  response  to  infection,  and  cytolysis. 
Specifically,  we  demonstrate  that  Bcl11b-deficient  CD8+  
T cells failed to efficiently expand in response to infection 
(C) Western blot analysis of perforin in purified CD8+ T cells from mice infected with Lm-Ova. Bcl11bF/F/dLck-iCre/OT1 and WT OT1 mice were infected  
with Lm-Ova, and 7 d after infection total CD8+ T cells were purified. Extracts were prepared from equal numbers of cells and Western blot analysis was 
conducted for evaluation of perforin. Data are representative of two independent experiments. (D) Relative mRNA levels of perforin and granzyme B  
(normalized to actin) in equal numbers of total CD8+ T cells purified form LM-Ova–infected Bcl11bF/F/dLck-iCre/OT1 and WT OT1 mice. Data are derived from  
multiple experiments with, respectively, 10 and 11 pairs of mice and, respectively, P = 0.0039 and 0.0001. * indicates significant difference. (E and F) ChIP 
assays with anti-Bcl11b or anti-GFP antibodies on purified CD8+ T cells from infected mice at day 6 after infection. Association of Bcl11b with perforin  
(E) and granzyme B (F) genomic regions was evaluated by qPCR using primers covering the indicated regions upstream of TSS, and values were expressed 
relative to the input as described in Materials and methods. Data are representative of two independent experiments on two pairs of mice. (G and H) Eval-
uation of perforin and granzyme B mRNA levels in CD8+ T cells from Bcl11bF/F/ER-Cre and ER-Cre mice in vitro stimulated for 2 d, before the initiation of 
the treatment with OH-tamoxifen, according to a protocol for in vitro differentiation to effector cells (Cruz-Guilloty et al., 2009). After activation, cells 
were grown in the presence of 100 U/ml rIL-2 and 100 nM OH-tamoxifen for 4–5 d and RNA was purified followed by qRT-PCR. This is representative of 
two independent experiments, each with two to three pairs of mice. P = 0.64 and 0.46, respectively. Error bars indicate SD.
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only regulate perforin and granzyme B expression under spe-
cific conditions, which might differ between in vivo and   
in vitro experiments. Although at the moment it is hard to have 
a clear answer because of the discrepancy between the in vivo 
and in vitro results, it is possible that in certain conditions 
Bcl11b might regulate expression of perforin and granzyme B. 
Other transcription factors, such as Eomes and Runx3, were 
also found to control the expression of the CTL effector mol-
ecules (Pearce et al., 2003; Intlekofer et al., 2005; Chen et al., 
2008; Cruz-Guilloty et al., 2009). Runx3 was found to asso-
ciate with perforin and granzyme B promoters (Cruz-Guilloty 
et al., 2009). There are several Runx3 consensus sequences in 
the perforin promoter. One such site is closely located to a 
Bcl11b consensus site (unpublished data), suggesting the pos-
sibility that these two transcription factors may function to-
gether by binding to adjacent sites. The granzyme B promoter 
has a region of TGTG repeats which may potentially consti-
tute binding sites for Runx3, and a Bcl11b consensus binding 
site resides very close to that (unpublished data), also suggest-
ing the possibility that the two transcription factors may bind 
to the adjacent sites on the granzyme B promoter. Such possi-
bilities are under investigation.
Bcl11b is expressed during T cell development, as well as 
in mature T cells, which suggests the possibility that it may 
regulate common genes in T cells and implicitly common   
genetic programs. Our observations suggest that, at least in   
DP thymocytes and CD8+ T cells, this is the case for certain 
genes (unpublished data); however, Bcl11b seems to differen-
tially regulate specific genes in CD8+ T cells versus DP thymo-
cytes, such as the CD8 coreceptor. How can Bcl11b regulate 
different genes in different T cell types, despite the fact that it is 
expressed at similar levels in these cells, rather than only regulat-
ing common genes? Bcl11b may cooperate with stage-specific 
transcription factors, and/or Bcl11b function may be modu-
lated by specific signals, including TCR signaling, such that it 
can play a differential role in specific T cell subtypes. Such pos-
sibilities are under investigation. In conclusion, our data dem-
onstrate that Bcl11b is a critical transcription factor for the 
CD8 immune response, controlling the expansion and execu-
tion of the effector function.
MATERIALS AND METHODS
Mice. Mice carrying the floxed Bcl11b alleles (Bcl11bF/F) were backcrossed 
on C57BL/6 background for nine generations and crossed with dLck-iCre 
C57BL/6 mice (gift from N. Killeen, University of California, San Francisco, 
San Francisco, CA) to generate conditional Bcl11bF/F/dLck-iCre mice. To 
obtain  OT-1  TCR/  Bcl11bF/F/dLck-iCre,  Bcl11bF/F/dLck-iCre  mice   
were crossed to OT-1 TCR transgenic mice (The Jackson Laboratory). 
CD45.1 mice were purchased from NCI or The Jackson Laboratory. Exper-
iments were conducted with 5–10-wk-old mice unless specified. All mice 
except for the infection model were kept under specific pathogen-free con-
ditions in the Albany Medical Center (AMC) Animal Facility, and all animal 
procedures were approved by the AMC Animal Care and Use Committee.
Cell culture, antibodies, and flow cytometry. Naive CD8+ T lympho-
cytes were either sorted as CD62LhiCD44lo population or purified by deple-
tion, using the CD8+ T cell depletion kit (Miltenyi Biotec). When using the 
Miltenyi depletion kit, the antibody cocktail was supplemented with 50 ng bio-
tinylated anti–mouse CD25 and anti–mouse CD44 antibodies per 107 cells to 
Such a possibility is currently under investigation. The re-
maining CD8 coreceptor levels in the absence of Bcl11b may 
be attributed to the E8II contribution, which is also known 
to control CD8 coreceptor expression in CD8+ T cells, in 
addition to the DP thymocytes (Ellmeier et al., 1997), to 
which Bcl11b did not bind. In the absence of Bcl11b in   
DP  thymocytes,  CD8  coreceptor  levels  were  not  altered, 
suggesting that Bcl11b does not control expression of CD8 
coreceptor in DP thymocytes (Albu et al., 2007). Therefore, 
our results demonstrate that Bcl11b is one of the transcription 
factors critical for the maintenance of the CD8 coreceptor 
levels in the periphery. In addition to the CD8 coreceptor, 
we found that Bcl11b regulates the expression of Plc1 in 
mature CD8+ T cells, which is another critical gene for TCR 
signaling (Wilde and Watson, 2001; Bonvini et al., 2003). In 
conclusion, our results suggest that TCR signaling in Bcl11b-
deficient CD8+ T cells is impaired by at least two mechanisms: 
reduced expression of CD8, and probably, therefore, less opti-
mal activation of CD8+ T cells, and reduced expression of Plc1 
and, hence, reduced Ca2+ mobilization.
After Ag-specific activation, naive CD8+ T lymphocytes 
expand and differentiate into effector cytotoxic T cells. The 
effector Klrg1hiIL7Rlo CTL population was formed in the 
absence of Bcl11b, although in reduced numbers. The pro-
duction of perforin and granzyme B, evaluated in equivalent 
numbers of CTLs from infected mice, was altered. More-
over, the perforin and granzyme B mRNAs were reduced in 
CD8+  T  cells  purified  from  LM-Ova–infected  mice,  and 
ChIP experiments demonstrated that Bcl11b bound to both 
perforin and granzyme B genomic regions upstream of their 
TSS in CTLs from infected mice. Unexpectedly, removal of 
Bcl11b after in vitro activation did not result in reduced per-
forin and granzyme B mRNA levels, suggesting that perhaps 
the reduction in perforin and granzyme B levels during infec-
tion is caused in part by suboptimal TCR activation. How-
ever, the fact that Bcl11b-deficient CTLs on a per cell basis 
had a reduced capacity to kill Ag-specific MEC.B7.SigOva 
target cells suggests that the reduced clonal expansion is not 
solely responsible for the altered cytolytic activity because in 
this assay equal numbers of Bcl11b-deficient and WT CTLs 
were compared. Thus, other possibilities for the differences 
that we observed between the in vivo versus the in vitro 
conditions include: growth of Bcl11b-deficient CD8+ T cells 
in vitro for several days might select a specific population, 
and/or might only favor survival of certain cells; the absence 
of specific conditions which are only present in vivo, but not 
in vitro; or in vivo removal of the gene with the dLckD-iCre 
before TCR activation, as opposed to in vitro removal af-
ter activation, could have different effects on CD8+ T cell 
activation/differentiation.
With regard to the presence of Bcl11b on genomic re-
gions upstream of TSS of perforin and granzyme B genes, 
there are multiple possibilities: the presence of a transcription 
factor on promoter/enhancer does not always result in regula-
tion of expression; or the presence of Bcl11b on genomic re-
gions upstream of perforin and granzyme B TSS genes might JEM VOL. 207, August 2, 2010 
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In vitro proliferation was evaluated by CFSE dilution. Bcl11b-deficient 
and WT naive CD8+ T lymphocytes were purified from OT-1 mice as shown 
in the previous paragraph. The naive CD8+ T cells were labeled with 5 µM 
CFSE and incubated for 3 d with APCs pulsed with 0 or 0.1 µM OVA257-264 
peptide, for 2 d in media with 2 µg/ml of soluble -CD28 and 0.5 µg/ml of 
cross-linked -CD3, or in media with 10 nM PMA and 1 µM ionomycin. Cell 
divisions were assessed by tracking the dilution of CFSE by flow cytometry.
ChIP. ChIP was conducted using CD8+ T cells purified on beads (Miltenyi 
Biotec), according to our previously published protocol (Cismasiu et al., 2006), 
with the difference that anti-Bcl11b antibodies were preloaded on anti–rabbit 
IgG-Dynabeads (Invitrogen), and the precipitated DNA was analyzed by qPCR. 
As a control, we used either anti-GFP antibodies or IgG. The primers for CD8 
enhancers I, II, III, IV, and V were previously described (Sato et al., 2005). The 
transcription factor–bound DNA was calculated based on the following formula: 
2ct of the immunoprecipitated sample divided by 2ct of the input, where ct is 
the threshold cycle, followed by corrections for the input dilution.
qRT-PCR. qRT-PCR from total RNA purified from naive or total CD8+ 
T lymphocytes, from naive mice, or from LM-Ova–infected mice was con-
ducted as previously described (Cismasiu et al., 2006), always using primers 
that cross introns.
Statistical analysis. Differences between Bcl11bF/F/dLck-iCre and control 
mice under all experimental conditions were analyzed by the two-tailed 
Student’s t test and expressed as the mean ± the SD. P ≤ 0.05 was considered 
significant for all analyses.
Online  supplemental  material.  Fig.  S1  shows  conditional  removal  of 
Bcl11b in mature T cells with the use of the dLck-iCre system. Fig. S2 shows 
TCR- on CD4 and CD8 SP thymocytes of Bcl11bF/F/dLck-iCre mice. Fig. S3 
shows histograms showing cleaved caspase-3 levels on gated CD45.1 recipient 
CD8+ T cell populations. Fig. S4 shows that acute removal of Bcl11b in vivo 
with the use of ER-Cre deleter results in reduced CD8 coreceptor levels. 
Fig. S5 shows that Bcl11b does not bind actin promoter, the distal CTL- 
specific DNase I hypersensitive site in the perforin locus, or a genomic region 
located 1 kb downstream of the granzyme B stop codon. Table S1 shows CD8 
MFI in SP thymocytes and CD8+ T lymphocytes of Bcl11bF/F/dLck-iCre and 
Bcl11bF/F mice. Table S2 shows ratios of CD8 MFI of Bcl11bF/F/dLck-iCre 
and Bcl11bF/F CD8+ T lymphocytes. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20092136/DC1.
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isolate mostly naive cells. The purity of CD44loCD8+ T cells after purifica-
tion was always >95%. The following antibodies (eBioscience) were used for   
surface and intracellular staining: anti-CD4 (clone GK1.5), -CD8 (clone   
53–6.7), -CD8 (clone eBioH35-17.2), -CD45.1 (clone A20), -CD45.2 (clone 
104), -CD69 (clone H1.2F3), -CD127 (clone A7R34), -Klrg1 (clone 2F1),   
–TCR- (clone H57-597), -BrdU (clone PRB-1), –granzyme B (clone 16G6), 
and -perforin (clone eBioOMAK-D). Intranuclear staining of Bcl11b was 
conducted after staining for surface CD4 and CD8, followed by fixation and 
permeabilization with 1% Triton X-100 (Albu et al., 2007). Determination of 
apoptosis was conducted by intracellular staining with anti-cleaved caspase 3 
antibodies (Cell Signaling Technology) after surface staining. Antibodies for 
Western blot analysis were: anti-Bcl11b (Bethyl Laboratories, Inc.), -perforin 
(Abcam), and P-Zap70 and Zap70 (Cell Signaling Technology).
Granzyme staining for flow cytometry analysis. 1–2 × 106 immune cells 
were stained with antibodies against surface markers for 30 min on ice. Cells 
were then fixed with freshly prepared Fixation/Permeabilization working solu-
tion (eBioscience) at 4°C for 30–60 min. After washing twice with permeabili-
zation buffer (eBioscience), cells were incubated in permeabilization buffer at 
4°C for 15 min, followed by addition of fluorophore-labeled anti–mouse gran-
zyme antibodies (clone 16G6; eBioscience). Cells were then incubated on ice for 
30 min in the dark, after which the cells were washed in the same permeabiliza-
tion buffer and resuspended in staining buffer for flow cytometry analysis.
Flow  cytometry  analysis. Flow cytometry analysis was conducted on 
FACSCalibur or FACSCanto flow cytometers (BD). Flow cytometry data 
were analyzed using FlowJo software (Tree Star, Inc.).
Bone marrow reconstitution. For influenza infection experiments, mixed 
bone marrow chimeras were generated by lethally irradiating CD45.1 recipi-
ent mice and reconstituting them with either a 1:1 mix of CD45.1 and 
CD45.2  C57BL/6  bone  marrow  (WT:WT  chimeras)  or  a  1:1  mix  of 
CD45.1 and CD45.2 Bcl11bF/F/dLck-iCre bone marrow (WT:KO) chime-
ras. After reconstitution, mice were infected with 1,000 EIU of PR8. The 
frequencies of NP-specific and PA-specific CD8 T cells derived from each 
donor type were determined by flow cytometry in the mediastinal lymph 
nodes on day 10 after infection.
Adoptive transfers, Lm-Ova infection, and bacterial burden. Sorted 
naive  CD44lo  CD8+  T  lymphocytes  from  CD45.2  Bcl11bF/F/dLck-iCre/ 
OT-1 and CD45.1/2/OT-1 mice (1:1; total 104) were intravenously injected 
either together or separately into CD45.1 recipient mice. The next day after 
transfer, recipient mice were injected with 1.5 × 104 CFU Lm-Ova (Shen et al., 
1995). Bacterial burden was assessed in the livers and spleens of Lm-Ova– 
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